To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

Inclusion Criteria: * Post-menarchal female subjects must have a negative urine pregnancy test * Willing to provide written informed consent/assent * Diagnosed as having mild to moderate Atopic Dermatitis (AD) * Willing to stop all moisturizers and/or other skin barrier cream or emulsion treatments for the AD condition during the test period and replace with the investigational product assigned in this trial * Willing to replace their body wash and/or soaps with the one provided in this trial Exclusion Criteria: * Severe AD as determined by the Rajka-Langeland Severity Index * AD requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids. If the subject requires any of these medications as rescue therapy during the study, the subject will be discontinued from the trial * History of allergy or hypersensitivity to the ingredients of the test devices, nuts or nut oil * Cutaneous or systemic viral (including HIV or AIDS), mycotic or bacterial disease requiring a topical or systemic therapy * Diabetes mellitus that cannot be controlled by diet alone (i.e., requires systemic medications for control)